Factors influencing scar formation following Bacille Calmette-Guérin (BCG) vaccination

The prevalence of scar formation following Bacille Calmette-Guérin (BCG) vaccination varies globally. The beneficial off-target effects of BCG are proposed to be stronger amongst children who develop a BCG scar. Within an international randomised trial (‘BCG vaccination to reduce the impact of coron...

Full description

Saved in:
Bibliographic Details
Published in:Heliyon 2023-06, Vol.9 (6), p.e15821, Article e15821
Main Authors: Villanueva, Paola, Crawford, Nigel W., Croda, Mariana Garcia, Collopy, Simone, Jardim, Bruno Araújo, de Almeida Pinto Jardim, Tyane, Manning, Laurens, Lucas, Michaela, Marshall, Helen, Prat-Aymerich, Cristina, Sawka, Alice, Sharma, Ketaki, Troeman, Darren, Wadia, Ushma, Warris, Adilia, Wood, Nicholas, Messina, Nicole L., Curtis, Nigel, Pittet, Laure F.
Format: Article
Language:English
Subjects:
BCG scar
BCG vaccine
Corrigendum
Vaccination technique
Vaccine safety
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The prevalence of scar formation following Bacille Calmette-Guérin (BCG) vaccination varies globally. The beneficial off-target effects of BCG are proposed to be stronger amongst children who develop a BCG scar. Within an international randomised trial (‘BCG vaccination to reduce the impact of coronavirus disease 2019 (COVID-19) in healthcare workers’; BRACE Trial), this nested prospective cohort study assessed the prevalence of and factors influencing scar formation, as well as participant perception of BCG scarring 12 months following vaccination. Amongst 3071 BCG-recipients, 2341 (76%) developed a BCG scar. Scar prevalence was lowest in Spain and highest in UK. Absence of post-injection wheal (OR 0.4, 95%CI 0.2–0.9), BCG revaccination (OR 1.7, 95%CI 1.3–2.0), female sex (OR 2.0, 95%CI 1.7–2.4), older age (OR 0.4, 95%CI 0.4–0.5) and study country (Brazil OR 1.6, 95%CI 1.3–2.0) influenced BCG scar prevalence. Of the 2341 participants with a BCG scar, 1806 (77%) did not mind having the scar. Participants more likely to not mind were those in Brazil, males and those with a prior BCG vaccination history. The majority (96%) did not regret having the vaccine. Both vaccination-related (amenable to optimisation) and individual-related factors affected BCG scar prevalence 12 months following BCG vaccination of adults, with implications for maximising the effectiveness of BCG vaccination.
ISSN:2405-8440
2405-8440
DOI:10.1016/j.heliyon.2023.e15821